A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis
This study will look at the safety, tolerability, and efficacy of an investigational drug called ocrelizumab in patients with primary progressive multiple sclerosis (PPMS). Ocrelizumab is an experimental drug, which means that it is still being tested and is not yet approved by the US Food and Drug Administration (FDA).
Ocrelizumab is a kind of drug called a monoclonal antibody. An antibody is a type of protein that helps to protect the body against foreign materials such as germs and viruses. A monoclonal antibody is a specialized laboratory-produced antibody that recognizes a specific region on certain cells. Ocrelizumab is a monoclonal antibody which is designed to destroy a type of white blood cell called a B-cell, which is believed to play a role in some of the symptoms of MS.
One-third of study participants will receive a placebo, which contains no active drug treatment. Two-thirds will receive ocrelizumab. During the main treatment phase of the study, participants will not know if the treatment they are receiving is a placebo or ocrelizumab.
Closed to enrollment